Want to see TSE:RVX full AI Analyst Report?
RVX Stock Chart & Stats
C$0.10
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.10
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.30
Previous CloseN/A
Volume1.00K
Average Volume (3M)37.18K
Market Cap
C$34.39M
Enterprise ValueC$97.50M
Total Cash (Recent Filing)C$50.03K
Total Debt (Recent Filing)C$75.06M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding343,916,100
10 Day Avg. Volume62,041
30 Day Avg. Volume37,183
Financial Highlights & Ratios
PEG Ratio-7.26
Price to Book (P/B)-0.23
Price to Sales (P/S)0.00
P/FCF Ratio-5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Epigenetic/BET-targeted PipelineA clear scientific focus on epigenetic mechanisms and BET proteins gives the company a defined R&D thesis and potential differentiation in cardiovascular/metabolic and inflammatory therapeutics. This durable scientific niche can create high barriers to competition and supports targeted partnership or licensing opportunities over months to years.
Integrated Development-to-partnering Business ModelOperating across discovery, clinical development and seeking commercialization via partnerships is a sustainable model for a small biotech: it lets the company focus on value-creating R&D while de-risking capital-intensive commercialization through partners, preserving runway and strategic flexibility over the medium term.
Modest Improvement In Free Cash Flow (2024→2025)The reported reduction in negative free cash flow from 2024 to 2025 and modest asset growth signal early operational efficiency gains. If sustained, this trend can reduce near-term external funding needs and slightly improve balance sheet resilience over the next several quarters, aiding execution of development milestones.
Bears Say
No Revenue Across Reported PeriodsPersistent absence of revenue means the business has no operating income to fund R&D or operations, leaving clinical progress wholly dependent on external financing or partnerships. Over 2–6 months this limits strategic flexibility and raises execution risk if funding windows narrow.
Consistent Cash Burn And Negative Cash GenerationSustained negative operating and free cash flow forces recurring financing, increasing dilution risk and creating dependency on capital markets or partners. This structural cash-burn profile constrains long-term planning and can delay or jeopardize clinical programs absent reliable funding sources.
Highly Stressed Balance Sheet; Negative Equity, Debt > AssetsDeeply negative equity and debt levels that exceed assets create material solvency and refinancing risk. This structural leverage can limit access to favorable financing, force expensive or dilutive capital raises, and reduce strategic options for partnerships or asset-backed transactions over the medium term.
Resverlogix News
RVX FAQ
What was Resverlogix Corp. J’s price range in the past 12 months?
Resverlogix Corp. J lowest stock price was C$0.09 and its highest was C$0.30 in the past 12 months.
What is Resverlogix Corp. J’s market cap?
Resverlogix Corp. J’s market cap is C$34.39M.
When is Resverlogix Corp. J’s upcoming earnings report date?
Resverlogix Corp. J’s upcoming earnings report date is Aug 19, 2026 which is in 26 days.
How were Resverlogix Corp. J’s earnings last quarter?
Currently, no data Available
Is Resverlogix Corp. J overvalued?
According to Wall Street analysts Resverlogix Corp. J’s price is currently Overvalued.
Does Resverlogix Corp. J pay dividends?
Resverlogix Corp. J does not currently pay dividends.
What is Resverlogix Corp. J’s EPS estimate?
Resverlogix Corp. J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Resverlogix Corp. J have?
Resverlogix Corp. J has 343,916,100 shares outstanding.
What happened to Resverlogix Corp. J’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Resverlogix Corp. J?
Currently, no hedge funds are holding shares in TSE:RVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Resverlogix Corp. J
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Technical Analysis
XORTX Therapeutics Inc
―
BriaCell Therapeutics
―
Microbix Biosystms
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―